Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
McKinsey
UBS
QuintilesIMS
Harvard Business School
Fuji
Deloitte
Cerilliant
Mallinckrodt

Generated: January 21, 2019

DrugPatentWatch Database Preview

Rigel Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for RIGEL PHARMS INC, and when can generic versions of RIGEL PHARMS INC drugs launch?

RIGEL PHARMS INC has one approved drug.

There are fourteen US patents protecting RIGEL PHARMS INC drugs.

There are seventy-eight patent family members on RIGEL PHARMS INC drugs in thirty-four countries.

Summary for Rigel Pharms Inc
International Patents:78
US Patents:14
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Rigel Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rigel Pharms Inc TAVALISSE fostamatinib disodium TABLET;ORAL 209299-002 Apr 17, 2018 RX Yes Yes 8,263,122 ➤ Try a Free Trial Y ➤ Try a Free Trial
Rigel Pharms Inc TAVALISSE fostamatinib disodium TABLET;ORAL 209299-002 Apr 17, 2018 RX Yes Yes 7,538,108 ➤ Try a Free Trial Y ➤ Try a Free Trial
Rigel Pharms Inc TAVALISSE fostamatinib disodium TABLET;ORAL 209299-001 Apr 17, 2018 RX Yes No 9,283,238 ➤ Try a Free Trial ➤ Try a Free Trial
Rigel Pharms Inc TAVALISSE fostamatinib disodium TABLET;ORAL 209299-002 Apr 17, 2018 RX Yes Yes 9,737,554 ➤ Try a Free Trial Y ➤ Try a Free Trial
Rigel Pharms Inc TAVALISSE fostamatinib disodium TABLET;ORAL 209299-001 Apr 17, 2018 RX Yes No 7,538,108 ➤ Try a Free Trial Y ➤ Try a Free Trial
Rigel Pharms Inc TAVALISSE fostamatinib disodium TABLET;ORAL 209299-002 Apr 17, 2018 RX Yes Yes 7,989,448 ➤ Try a Free Trial Y ➤ Try a Free Trial
Rigel Pharms Inc TAVALISSE fostamatinib disodium TABLET;ORAL 209299-001 Apr 17, 2018 RX Yes No 8,445,485 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Rigel Pharms Inc Drugs

Country Document Number Estimated Expiration
Denmark 2078026 ➤ Try a Free Trial
Japan 2008527048 ➤ Try a Free Trial
New Zealand 555947 ➤ Try a Free Trial
European Patent Office 1856135 ➤ Try a Free Trial
South Korea 101278397 ➤ Try a Free Trial
Cyprus 1109888 ➤ Try a Free Trial
Portugal 1856135 ➤ Try a Free Trial
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Daiichi Sankyo
US Department of Justice
Johnson and Johnson
Medtronic
Chinese Patent Office
QuintilesIMS
Farmers Insurance
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.